Analys

Faron Pharmaceuticals: Bexmarilimab Continues To Impress - Redeye

{newsItem.title}

Redeye Publicerad: 16 Jan 2023 11:59

Faron Pharmaceuticals

Redeye leaves a note following an announced trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab. We remain encouraged by the continued positive development and response to treatment.

Länk till analysen i sin helhet: https://www.redeye.se/research/871069/faron-pharmaceuticals-bexmarilimab-continues-to-impress?utm_source=finwire&utm_medium=RSS

Nyheter om Faron Pharmaceuticals

Läses av andra just nu

Om aktien Faron Pharmaceuticals

Senaste nytt